The First International Ivermectin for Covid Conference
Held 24th to 25th April 2021 | Online
The first ever conference focusing on the use of ivermectin (IVM) as a prophylaxis and treatment for covid-19.
Overview
Medical experts from around the world joined together to present the very latest real world research on repurposing this safe drug that has the ability to transform global efforts to fight the pandemic.
Topics include:
- Mechanism of IVM for covid-19
- Protocols for prevention and treatment
- Treating Long Covid with IVM
- Weight of Evidence with real world data
- Up to the minute reports on trials
- IVM for the elderly
Our Speakers
Dr. Mobeen Syed, Dr. Tess Lawrie, Prof. Pierre Kory, Prof. Hector Carvallo, Mr Juan Jose Chamie Quintero, Mr Andrew Bryant, Dr. David Chesler, Prof. Eli Schwartz, Dr. Wasif Khan, Dr. Manjul Medhi, Prof. Matjaž Zwitter. More info on speakers >>
Programme of days
Watch all of Day 1 again
Running time
Day 1 - 24 April. Chair: Dr. Mobeen Syed
2pm to 6pm GMT | 3pm to 7pm BST
Start times: New York 10am, South Africa 4pm, Sydney 12 am, Lima 9am
14:00 - 14:30 GMT
15:00 – 15:30 BST
1. What is ivermectin and how does it work?
Dr. Mobeen Syed provides an overview of ivermectin and how it works against covid-19.
30 minutes
14:30 - 15:15 GMT
15:30 – 16:15 BST
2. Ivermectin evidence update
Dr. Tess Lawrie presents the latest systematic review evidence from RCTs and a selection of resource, equity, acceptability and feasibility considerations related to ivermectin use.
45 minutes
Break 15:15-15:45 GMT | 16:15 – 16:45 BST
15:45 - 16:30 GMT
16:45 – 17:30 BST
3. Real world data
Mr. Juan Chamie presents the latest real world data from countries using ivermectin, including the European data.
45 minutes
Break 16:30 – 16:45 GMT | 17:30 – 17:45 BST
16:45 - 17:15 GMT
17:45 – 18:15 BST
4. Ongoing Trials
Mr. Andrew Bryant provides an overview of ongoing trials and what they may add to the evidence base.
30 minutes
17:15 - 17:45 GMT
18:15 – 18:45 BST
5. Ivermectin use in the elderly
Dr. David Chesler shares his experience of using ivermectin to prevent and treat covid-19 infection amongst care home residents.
30 minutes
17:45 - 18:00 GMT
18:45 – 19:00 BST
6. Summary of 1st day by Dr. Mobeen Syed
Day 2 - 25 April. Chair: Dr. Mobeen Syed
2pm to 6:15pm GMT | 3pm to 7:15pm BST
NOTE: All times listed are GMT.
Add 1 hour for BST
14:00 - 14:30 GMT
15:00 – 15:30 BST
1. Recent findings from the Israeli trial of ivermectin versus placebo
Prof. Eli Schwartz shares data and conclusions from his Israeli RCT of ivermectin in mild to moderate covid-19.
30 minutes
14:30 - 15:00 GMT
15:30 – 16:00 BST
2. Protocols for prophylaxis and treatment of acute covid-19
Prof. Pierre Kory discusses current protocols for covid-19 prevention and treatment.
30 minutes
15:00 – 15:30 Break
15:30 - 16:00 GMT
16:30 – 17:00 BST
3. Experiences with ivermectin in Bangladesh
30 minutes
16:00 - 16:30 GMT
17:00 – 17:30 BST
4. Experience with ivermectin and long covid in South America.
Prof. Héctor Carvallo shares his experiences with using ivermectin for long covid.
30 minutes
Followed by a short presentation by Dr Tina Peer, UK GP who will describe her real world experiences treating Long Covid
Break
16:30 – 17:00 GMT | 17:30 – 18:00 BST
17:00-17:30 GMT
18:00 – 18:30 BST
5. Experiences of a frontline Infectious Diseases doctor in Scotland
Dr. Manjul Medhi shares his front line experiences in treating acute and long covid including using ivermectin in patients at risk of disseminated strongyloides infection.
30 minutes
17:30 - 18:00 GMT
18:30 – 19:00 BST
6. Medical ethics and ivermectin
Prof. Matjaž Zwitter presents current ethical issues around ivermectin for covid-19.
30 minutes
18:00 - 18:15 GMT
19:00 – 19:15 BST
7. Summary and closing statement by Dr. Mobeen Syed.
Our Speakers
Dr. Mobeen Syed
Mobeen Syed M.D., M.S., graduated from King Edward Medical University in 1994. After practicing clinical medicine for a few years, he continued his studies in Computer Science with the goal of merging innovative technologies and healthcare. Dr. Mobeen’s dedication for teaching began at Horizon Medical Institute. enables them to learn medicine in conjunction with new technologies.
Dr. Mobeen’s unique skillset as a physician and software engineer enabled him to innovate several products, including a portable 3D ultrasound system designed by MediTeQ RI. His experience as a high tech executive includes time at Staples, Kohl’s, Rue Lala, Gemvara, TJX, and most recently e-commerce giant, PayPal.
Dr. Mobeen’s dedication to innovative and pioneering medical education has been a mainstay in his life. At DrBeen Corp, he strives to create a managed marketplace for medical providers that enables them to learn medicine in conjunction with new technologies.
Dr. Tess Lawrie
Tess (MBBCh, PhD), is the Director of E-BMC Ltd, and EbMCsquared, a community interest research company. Tess is committed to improving the quality of healthcare through rigorous research. Her range of research expertise, based on research experience in both developing and developed countries, uniquely positions her to evaluate and design research for a variety of healthcare settings. Tess is a frequent member of technical teams responsible for developing international guidelines. Her peer-reviewed publications have received in excess of 3000 citations and her ResearchGate score is among the top 5% of ResearchGate members.
Dr. Pierre Kory, MD, MPA
Dr. Kory has travelled across multiple states in the US to care for COVID-19 patients throughout the pandemic and is also the President and Chief Medical Officer of the Front Line COVID-19 Critical Care Alliance, a non-profit organization of critical care specialists led by Professor Paul Marik whose mission over the past 9 months has been focused on the research and development of effective treatment protocols for COVID-19 using repurposed drugs. Most recently, based on his extensive research over the past 6 months, he has become one of the most sought-after experts on the use of ivermectin in the prevention and treatment of COVID-19.
Dr. Héctor Carvallo
Nati Professor, Universidad Abierta Interamericana – Argentina Ivermectine and Carrageenan in the Prevention of COVID-19.
Prof. Carvallo is former Professor of Medicine at the University of Buenos Aires, as well as Former Director of the Ezeiza Public Hospital in Argentina. Currently he is involved in the development of strategies to defeat SARs COV 2, and has been a vocal advocate of ivermectin. Recently, he was appointed as Editor in Chief of the newly released OAJ Research & Applied Medicine.
Dr. David Chesler
Internal Medicine Physician, private practice. Charlottesville Family Medicine 1980-Present. Diplomate of American Board of Internal Medicine. Board Certified in Geriatric Medicine
Prof. Matjaž Zwitter, MD, PhD
Head of the Department of Medical Ethics and Law, Medical Faculty, University of Maribor, Slovenia. His two papers on ivermectin for Covid-19, as published in Slovenian medical journal Isis and in leading newspaper Delo stirred a vivid debate among medical and lay community, hopefully leading to a change in current medical practice.
He was co-editor of two books on communication: Communication with the cancer patient: information and truth (The New York Academy of Sciences 1997) and New challenges in communication with cancer patients ( Springer 2013). He also wrote and published three books: Talking about medical ethics (in Slovenian language, Cankarjeva založba 2018), Medical Ethics in Clinical Practice (Springer 2019) and Talking on euthanasia (in Slovenian language, Slovenska matica 2019).
Dr. Wasif Khan
Enteric and Respiratory Infections. Infectious Diseases Division (IDD). International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b). Bangladesh Clinical Trials Limited (BCTL)
Juan Chamie
Juan Chamie is a Senior Data Analyst who has been tirelessly researching and spreading the word of ivermectin since early May, 2020. Like the rest of the world, Mr. Chamie closely followed the spread of COVID-19, and his interest in ivermectin was piqued when a doctor in the Dominican Republic used the drug successfully to treat the illness.
Quickly thereafter, a major outbreak in Iquitos, Peru, and local health officials’ successful use of ivermectin to curb the disease, launched Juan’s months-long investigation into widespread efficacy of the drug. Using data as his compass, he showcased his results in stunning data visualizations, and has been using his findings to try to convince health officials and leaders across the world of the positive results of this easily-accessible, highly-affordable drug.
Juan has expanded his scope and he is analyzing data of ivermectin intervention all over the globe.
Prof. Eli Schwartz
Director of the Center for Geographic Medicine at Sheba Medical Center in Tel-Hashomer Israel, first introduced the field of travel medicine to Israel .
His practice became the recognized center by the Ministry of Health of Israel for tropical and travel diseases. Dr Schwartz is currently serving as the president of the Israeli Society of Parasitology and Tropical Diseases and past president of the Asia-Pacific Travel Health Society. He is a full Professor (clinical) at the Sacker faculty of Medicine, Tel-Aviv University.
Dr. Manjul Medhi
Dr. Medhi has been working as a Consultant in Infectious Diseases (ID) at Forth Valley Royal Hospital (FVRH) since October 2017.
Since that time he has been part of a small team setting up a brand new Infectious Diseases and OPAT service.
He has previously worked as a junior doctor in several ID departments in the UK including Aberdeen, Dumfries, Newcastle, Liverpool, Manchester and in London.
As well as an interest in service development he also has an interest in medical education and has previously worked for the University of Aberdeen for two years as a Clinical Teaching Fellow.
Andrew Bryant
Biostatistician with experience in clinical trials and systematic review methodology based at Newcastle University. A vast number of systematic review and study publications. An avid football, cricket and golf fan!
Dr Tina Peers
She gained her Menopause Specialist qualification whilst working at Chelwest.
She now runs The Menopause Consultancy concentrating on women’s health.
For the last six years she has had an interest in Mast Cell Activation Syndrome and Histamine Intolerance sparked by diagnosing her daughter In 2016.
Since then she has helped many patients with this condition to improve their health and quality of life.
More latterly she has been treating Long Covid patients.
Disclaimer: Nothing on this Website provides medical advice or any form of diagnosis or treatment of any kind to web users. Medical decisions should be made by the patient’s physician who can consider a review of the BIRD materials and knowledge of the patient’s medical history and condition. All information provided on the BIRD website or in connection with the Website are offered to promote consideration by trained health care professionals of possible treatments and for general informational purposes and are not medical advice to users. Errors and Omissions excepted.
Transparency Statement: The team at Bird are transparent in our operations. Bird is a campaign managed through EbMCsquared, a not-for-profit Community Interest Company. It means 100% of profits after tax are reinvested into the business or to the advancement of our social purpose, for example to work on projects such as the Ivermectin campaign. We are here to promote and provide evidence for health and wellbeing, to inform decision-making on matters of public health and safety. We do this to advance health and wellbeing for the benefit of humankind.
